Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens

Vaccine

Volumn 35, Issue 1, 2017, Pages 1-9

  Penaloza MacMaster, Pablo ^a,e   Shields, Jennifer L ^a   Alayo, Quazim A ^a   Cabral, Crystal ^a   Jimenez, Jessica ^a   Mondesir, Jade ^a   Chandrashekar, Abishek ^a   Cabral, Joseph M ^a   Lim, Matthew ^a   Iampietro, M Justin ^a   Provine, Nicholas M ^a   Bricault, Christine A ^a   Seaman, Michael ^a   Orlinger, Klaus ^b   Aspoeck, Andreas ^b   Fuhrmann, Gerhard ^b   Lilja, Anders E ^b   Monath, Thomas ^b   Mangeat, Bastien ^c   Pinschewer, Daniel D ^c   Barouch, Dan H ^a,d   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HOOKIPA BIOTECH AG   (Austria)

^c UNIVERSITY OF BASEL   (Switzerland)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

LCMV; NHP; SIV

Indexed keywords

ANTIBODY; GAG PROTEIN; REPLICATION DEFECTIVE YMPHOCYTIC CHORIOMENINGITIS VIRUS VECTOR; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; DRUG CARRIER; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; EPITOPE MAPPING; IMMUNIZATION; IMMUNOGENICITY; MACACA FASCICULARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS TITRATION; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; IMMUNOLOGY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DRUG CARRIERS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACACA FASCICULARIS; MICE, INBRED C57BL; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84999837718     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.063     Document Type: Article

References (41)

1. [1] Dudek, T., Knipe, D.M., Replication-defective viruses as vaccines and vaccine vectors. Virology, 344, 2006, 230.
2. [2] Barouch, D.H., Picker, L.J., Novel vaccine vectors for HIV-1. Nat Rev Microbiol, 12, 2014, 765.
3. [3] Abbink, P., et al. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol, 89, 2015, 1512.
4. [4] Hansen, S.G., et al. Immune clearance of highly pathogenic SIV infection. Nature, 502, 2013, 100.
5. [5] Hansen, S.G., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature, 473, 2011, 523.
6. [6] Barouch, D.H., et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine, 29, 2011, 5203.
7. [7] Elbers, A.R., et al. Low prevalence of antibodies against the zoonotic agents Brucella abortus, Leptospira spp., Streptococcus suis serotype II, hantavirus, and lymphocytic choriomeningitis virus among veterinarians and pig farmers in the southern part of The Netherlands. Vet Q, 21, 1999, 50.
8. [8] Lledo, L., Gegundez, M.I., Saz, J.V., Bahamontes, N., Beltran, M., Lymphocytic choriomeningitis virus infection in a province of Spain: analysis of sera from the general population and wild rodents. J Med Virol, 70, 2003, 273.
9. [9] Fischer, S.A., et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. New Engl J Med, 354, 2006, 2235.
10. [10] Welsh, R.M., et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol, 74, 2000, 2210.
11. [11] Williams, M.A., et al. Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. J Immunol, 167, 2001, 4987.
12. + T cell immunity. Nat Med, 16, 2010, 339.
13. [13] Sommerstein, R., et al. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog, 11, 2015, e1005276.
14. [14] Flatz, L., et al. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol, 86, 2012, 7760.
15. [15] Penaloza-MacMaster, P., et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol, 87, 2013, 1373.
16. [16] Seaman, M.S., et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol, 84, 2010, 1439.
17. [17] Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R., Ahmed, R., Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol, 77, 2003, 4911.
18. [18] Ahmed, R., Salmi, A., Butler, L.D., Chiller, J.M., Oldstone, M.B., Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med, 160, 1984, 521.
19. [19] Penaloza-MacMaster, P., et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med, 211, 2014, 1905.
20. [20] Lukashevich, I.S., et al. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch Virol, 149, 2004, 2319.
21. [21] Penaloza-MacMaster, P., et al. Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. J Virol, 88, 2014, 6243.
22. + T cell exhaustion during chronic viral infection. Immunity, 27, 2007, 670.
23. [23] Wherry, E.J., Blattman, J.N., Ahmed, R., Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol, 79, 2005, 8960.
24. [24] Wherry, E.J., T cell exhaustion. Nat Immunol, 12, 2011, 492.
25. [25] Stelekati, E., Wherry, E.J., Chronic bystander infections and immunity to unrelated antigens. Cell Host Microbe, 12, 2012, 458.
26. [26] Stelekati, E., et al. Bystander chronic infection negatively impacts development of CD8(+) T cell memory. Immunity, 40, 2014, 801.
27. [27] Crawford, A., et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity, 40, 2014, 289.
28. [28] Barber, D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439, 2006, 682.
29. [29] Ahmed, R., Oldstone, M.B., Organ-specific selection of viral variants during chronic infection. J Exp Med, 167, 1988, 1719.
30. [30] Sallusto, F., Geginat, J., Lanzavecchia, A., Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol, 22, 2004, 745.
31. [31] Gubser, P.M., et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat Immunol, 14, 2013, 1064.
32. [32] Wherry, E.J., Ahmed, R., Memory CD8 T-cell differentiation during viral infection. J Virol, 78, 2004, 5535.
33. [33] Whitney, J.B., et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature, 512, 2014, 74.
34. [34] Kong, R., et al. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection. J Virol, 86, 2012, 947.
35. [35] Malherbe, D.C., et al. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J Virol, 88, 2014, 12949.
36. [36] Liao, H.X., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 496, 2013, 469.
37. [37] Doria-Rose, N.A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature, 509, 2014, 55.
38. [38] Mascola, J.R., Montefiori, D.C., The role of antibodies in HIV vaccines. Annu Rev Immunol, 28, 2010, 413.
39. [39] Moir, S., Malaspina, A., Fauci, A.S., Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol, 18, 2011, 1317.
40. [40] Scheid, J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 458, 2009, 636.
41. [41] Alpert, M.D., et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog, 8, 2012, e1002890.